AVERSA, Antonio
 Distribuzione geografica
Continente #
NA - Nord America 3.360
EU - Europa 815
AS - Asia 284
SA - Sud America 24
AF - Africa 10
Totale 4.493
Nazione #
US - Stati Uniti d'America 3.346
IT - Italia 197
FI - Finlandia 157
SE - Svezia 150
UA - Ucraina 150
IN - India 145
CN - Cina 106
BG - Bulgaria 36
GB - Regno Unito 30
SG - Singapore 29
DE - Germania 27
RO - Romania 27
AR - Argentina 23
IE - Irlanda 16
CA - Canada 13
BE - Belgio 10
NL - Olanda 6
TG - Togo 4
EG - Egitto 3
CZ - Repubblica Ceca 2
RU - Federazione Russa 2
ZA - Sudafrica 2
CH - Svizzera 1
CL - Cile 1
ES - Italia 1
FR - Francia 1
IL - Israele 1
IR - Iran 1
KR - Corea 1
LU - Lussemburgo 1
MX - Messico 1
PL - Polonia 1
SC - Seychelles 1
TR - Turchia 1
Totale 4.493
Città #
Fairfield 616
Woodbridge 302
Ashburn 281
Houston 250
Seattle 237
Chandler 230
Cambridge 207
Wilmington 198
Ann Arbor 141
San Paolo di Civitate 99
Dearborn 96
Princeton 87
Helsinki 84
Beijing 77
Plano 75
Lawrence 72
Rome 67
Boston 45
Sofia 36
San Diego 33
Jacksonville 28
Millbury 27
Federal 23
Andover 20
Boardman 19
Des Moines 17
Dublin 16
Singapore 14
Norwalk 13
Toronto 11
Brussels 10
Falls Church 10
Auburn Hills 6
London 6
Fremont 5
New York 5
Bremen 4
Bühl 4
Hefei 4
Lomé 4
Los Angeles 4
Cairo 3
Frankfurt am Main 3
Fuzhou 3
San Mateo 3
Shenyang 3
Simi Valley 3
Albano Laziale 2
Angri 2
Bari 2
Dallas 2
Marlton 2
Milan 2
Nanchang 2
Nanjing 2
Prague 2
Pune 2
San Polo Dei Cavalieri 2
Southend 2
Wuhan 2
Amsterdam 1
Baotou 1
Bellusco 1
Berlin 1
Bern 1
Bonndorf 1
Buffalo 1
Büdelsdorf 1
Changsha 1
Chicago 1
Eindhoven 1
Entratico 1
Grafing 1
Guangzhou 1
Hounslow 1
Indiana 1
Istanbul 1
Jinan 1
Jinhua 1
Las Vegas 1
Laurel 1
Lauria 1
Luxembourg 1
Madrid 1
Mahé 1
Mexico City 1
Miami 1
Muizenberg 1
Nuremberg 1
Ottawa 1
Pomezia 1
Quzhou 1
Redmond 1
Redwood City 1
Rotterdam 1
San Francisco 1
San Francisco De Las Llagas 1
Scottsdale 1
Secaucus 1
Silverton 1
Totale 3.567
Nome #
Endothelial dysfunction and erectile dysfunction in the aging man 102
Changes in left ventricular repolarization after short-term testosterone replacement therapy in hypogonadal males 92
Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation? 91
A spontaneous, double-blind, double-dummy cross-over study on the effects of daily vardenafil on arterial stiffness in patients with vasculogenic erectile dysfunction 89
A pilot study to evaluate the effects of vardenafil on sexual distress in men with obesity 87
Cardiovascular effect of testosterone replacement therapy in aging male 85
Chronic sildenafil in men with diabetes and erectile dysfunction. 85
Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction 83
Erectile dysfunction in systemic sclerosis: Effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels 80
Coordinating care aspects related to sexual health in the aging male 80
The ENDOTRIAL Study: A spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction 78
Type 2 diabetes mellitus and testosterone: a meta-analysis study 77
Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction. a pilot study 77
Effects of testosterone on sexual function in men: results of a meta-analysis 76
Testosterone and Metabolic Syndrome: A Meta-Analysis Study 76
THERAPY OF ENDOCRINE DISEASE: Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. 75
Body composition in sarcopenic obesity: systematic review of the literature 71
An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors 70
Testosterone and metabolic syndrome: a meta-analysis study 68
Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa 68
Selective sparing of pain pathways in a patient with adult cerebral adrenoleukodystrophy. 68
CAG repeat testing of androgen receptor polymorphism: is this necessary for the best clinical management of hypogonadism? 68
Effects of Testosterone Undecanoate on Cardiovascular Risk Factors and Atherosclerosis in Middle-Aged Men with Late-Onset Hypogonadism and Metabolic Syndrome: Results from a 24-month, Randomized, Double-Blind, Placebo-Controlled Study 68
Erectile dysfunction: an overview 67
Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. 67
The application of digital pulse amplitude tonometry to the diagnostic investigation of endothelial dysfunction in men with erectile dysfunction 67
Age-associated (cardio) metabolic diseases and cross-talk between adipose tissue and skeleton: endocrine aspects 66
Hormonal supplementation and erectile dysfunction 66
Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. 66
Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study 66
Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: Effects of 3 years intermittent testosterone supplementation 66
Early endothelial dysfunction as a marker of vasculogenic erectile dysfunction in young habitual cannabis users 65
EFFECT OF CHRONIC BROMOCRIPTINE TREATMENT ON PSYCHOLOGICAL PROFILE OF PATIENTS WITH PRL-SECRETING PITUITARY-ADENOMAS 64
Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. 64
Diagnosing Erectile Dysfunction: The penile dynamic colour duplex ultrasound revisited. 63
Testosterone Supplementation and Sexual Function: A Meta-Analysis Study 63
Effects of 5-Year Treatment With Testosterone Undecanoate on Lower Urinary Tract Symptoms in Obese Men With Hypogonadism and Metabolic Syndrome 63
Chronic therapy with phosphodiesterase 5 inhibitor tadalafil has a sustained effect on endothelial function 62
Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study 61
Anxiety-induced failure in erectile response to intracorporeal prostaglandin-E1in non organic male impotence: a new diagnostic approach 61
Body-fat distribution and responsiveness of the pituitary-adrenal axis to corticotropin-releasing-hormone stimulation in sedentary and exercising women 60
Penile cutaneous temperature in systemic sclerosis: A thermal imaging study 59
Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. 59
Sexual dysfunction: A practical approach to men with premature ejaculation. 58
Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome 57
Type 2 diabetes mellitus and testosterone: a meta-analysis study 57
'The limited practical value of color Doppler sonography in the differential diagnosis of men with erectile dysfunction' by Slob et al: A different point of view 57
Testosterone replacement improves metabolic syndrome and inflammation independently of body fat mass changes 57
Erectile dysfunction: symptom or disease? 56
The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs 56
Penile involvement in Systemic Sclerosis: New Diagnostic and Therapeutic Aspects. 54
Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction 54
Rapid decline of fertility in a case of adrenoleukodystrophy. 54
Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. 54
Sildenafil and erectile dysfunction 53
Re-dosing of prostaglandin-E1 versus prostaglandin-E1 plus phentolamine in male erectile dysfunction:a dynamic color power Doppler study 52
Endothelial effects of drugs designed to treat erectile dysfunction. 49
A rationale for the use of testosterone "salvage" in treatment of men with erectile dysfunction failing phosphodiesterase inhibitors 49
The evolving role of testosterone in the treatment of erectile dysfunction 49
Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions. 46
Erectile dysfunction: expectations beyond phosphodiesterase type-5 inhibition 46
Platelet-derived growth factor (PDGF) and PDGF-receptors in rat corpus cavernosum: changes in expression after transient in vivo hypoxia 44
Testosterone and metabolic syndrome: a meta-analysis study 43
Peripheral arterial tonometry to measure the effects of vardenafil on sympathetic tone in men with lifelong premature ejaculation 42
Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs 37
Effects of Sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males 36
Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study 34
Trunk Fat Negatively Influences Skeletal and Testicular Functions in Obese Men: Clinical Implications for the Aging Male 33
The penile vasculature in systemic sclerosis: A duplex ultrasound study 31
Re-dosing of prostaglandin-E-1 versus prostaglandin-E-1 plus phentolamine in male erectile dysfunction: a dynamic color power Doppler study - Reply to HC Porst 31
Exposure to Phosphodiesterase Type 5 Inhibitors Stimulates Aromatase Expression in Human Adipocytes in vitro 29
The Risky Health Behaviours of Male Adolescents in the Southern Italian Region: Implications for Sexual and Reproductive Disease 28
Management of premature ejaculation: a clinical guideline from the Italian Society of Andrology and Sexual Medicine (SIAMS) 28
PROLACTIN RESPONSE TO A SINGLE ORAL-ADMINISTRATION OF CISAPRIDE AND CLEBOPRIDE IN NORMAL MALES 27
Effect of chronic therapy with phospodiesterase 5 inhibitor tadalafil on endothelial function 26
New oral agents for erectile dysfunction: what is changing in our practice? 18
Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with Systemic Sclerosis 17
Rapid decline of fertility in a case of adronoleukodystrophy 14
Totale 4.565
Categoria #
all - tutte 10.599
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.599


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019475 0 0 0 0 0 0 0 0 0 0 271 204
2019/20201.271 166 42 16 55 124 197 191 150 137 89 72 32
2020/2021292 39 63 20 13 2 18 10 19 45 26 28 9
2021/2022883 7 59 105 39 108 16 21 97 72 69 133 157
2022/2023816 158 225 25 85 108 84 15 33 48 6 25 4
2023/2024363 26 71 10 26 53 51 7 83 1 35 0 0
Totale 4.565